| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 46 | 2024 | 1152 | 6.460 |
Why?
|
| Pancreatic Neoplasms | 74 | 2024 | 5351 | 6.190 |
Why?
|
| Liver Neoplasms | 47 | 2024 | 4319 | 4.360 |
Why?
|
| Neoadjuvant Therapy | 54 | 2024 | 2821 | 4.350 |
Why?
|
| Adenocarcinoma | 55 | 2023 | 6315 | 3.830 |
Why?
|
| Carcinoma, Hepatocellular | 26 | 2023 | 2299 | 3.820 |
Why?
|
| Fluorouracil | 41 | 2024 | 1631 | 3.470 |
Why?
|
| Bile Duct Neoplasms | 17 | 2024 | 602 | 3.240 |
Why?
|
| Cholangiocarcinoma | 17 | 2024 | 550 | 3.240 |
Why?
|
| Carcinoma, Pancreatic Ductal | 29 | 2024 | 1724 | 3.160 |
Why?
|
| Esophageal Neoplasms | 23 | 2023 | 1648 | 2.510 |
Why?
|
| Radiotherapy, Intensity-Modulated | 22 | 2023 | 801 | 2.500 |
Why?
|
| Stomach Neoplasms | 20 | 2021 | 1423 | 2.440 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 24 | 2021 | 1660 | 2.370 |
Why?
|
| Anus Neoplasms | 13 | 2021 | 329 | 2.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2024 | 11712 | 2.070 |
Why?
|
| Radiosurgery | 13 | 2024 | 1343 | 1.820 |
Why?
|
| Radiotherapy Dosage | 35 | 2023 | 2897 | 1.810 |
Why?
|
| Esophagogastric Junction | 11 | 2023 | 341 | 1.620 |
Why?
|
| Leucovorin | 20 | 2024 | 641 | 1.590 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 9276 | 1.570 |
Why?
|
| Deoxycytidine | 12 | 2019 | 873 | 1.500 |
Why?
|
| Combined Modality Therapy | 41 | 2023 | 8552 | 1.340 |
Why?
|
| Gastrointestinal Neoplasms | 8 | 2023 | 951 | 1.290 |
Why?
|
| Radiotherapy, Conformal | 10 | 2016 | 549 | 1.200 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2021 | 4024 | 1.150 |
Why?
|
| Photons | 5 | 2019 | 581 | 1.140 |
Why?
|
| Neoplasm Staging | 49 | 2024 | 11152 | 1.140 |
Why?
|
| Tumor Burden | 13 | 2018 | 1895 | 1.000 |
Why?
|
| Intraoperative Care | 3 | 2019 | 768 | 0.940 |
Why?
|
| Radiotherapy, Adjuvant | 14 | 2022 | 1791 | 0.910 |
Why?
|
| Lymphopenia | 5 | 2024 | 280 | 0.890 |
Why?
|
| Colorectal Neoplasms | 16 | 2022 | 6853 | 0.860 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2020 | 184 | 0.840 |
Why?
|
| Organoplatinum Compounds | 7 | 2024 | 410 | 0.830 |
Why?
|
| Aged | 124 | 2024 | 169152 | 0.830 |
Why?
|
| Humans | 286 | 2024 | 760621 | 0.800 |
Why?
|
| Survival Rate | 34 | 2024 | 12808 | 0.780 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2014 | 640 | 0.770 |
Why?
|
| Colonic Neoplasms | 8 | 2024 | 2526 | 0.760 |
Why?
|
| Middle Aged | 130 | 2024 | 220352 | 0.760 |
Why?
|
| Gene Amplification | 4 | 2020 | 1085 | 0.750 |
Why?
|
| Radiodermatitis | 2 | 2019 | 58 | 0.750 |
Why?
|
| Radiotherapy | 11 | 2021 | 1504 | 0.730 |
Why?
|
| Male | 156 | 2024 | 359744 | 0.710 |
Why?
|
| Chemotherapy, Adjuvant | 20 | 2022 | 3529 | 0.700 |
Why?
|
| Prognosis | 41 | 2024 | 29658 | 0.680 |
Why?
|
| Aged, 80 and over | 61 | 2024 | 58995 | 0.670 |
Why?
|
| Retrospective Studies | 79 | 2024 | 80372 | 0.670 |
Why?
|
| Radiation-Sensitizing Agents | 8 | 2021 | 345 | 0.660 |
Why?
|
| Radiation Oncology | 8 | 2023 | 563 | 0.660 |
Why?
|
| Organs at Risk | 5 | 2020 | 358 | 0.660 |
Why?
|
| Radiation Injuries | 8 | 2020 | 1183 | 0.630 |
Why?
|
| Losartan | 2 | 2023 | 265 | 0.630 |
Why?
|
| Female | 149 | 2024 | 391270 | 0.630 |
Why?
|
| Feasibility Studies | 10 | 2023 | 5201 | 0.620 |
Why?
|
| Laparotomy | 2 | 2018 | 465 | 0.620 |
Why?
|
| Head and Neck Neoplasms | 6 | 2015 | 2882 | 0.620 |
Why?
|
| Disease-Free Survival | 18 | 2024 | 6828 | 0.610 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2022 | 2007 | 0.610 |
Why?
|
| Intestine, Small | 3 | 2013 | 1207 | 0.590 |
Why?
|
| Radiation Tolerance | 7 | 2019 | 480 | 0.570 |
Why?
|
| Treatment Outcome | 42 | 2024 | 65017 | 0.550 |
Why?
|
| Liver Failure | 1 | 2019 | 249 | 0.550 |
Why?
|
| Lymph Nodes | 6 | 2019 | 3486 | 0.540 |
Why?
|
| Cholecystitis | 1 | 2017 | 181 | 0.530 |
Why?
|
| Gastrectomy | 7 | 2020 | 679 | 0.520 |
Why?
|
| Pancreatectomy | 7 | 2023 | 810 | 0.520 |
Why?
|
| Positron-Emission Tomography | 15 | 2024 | 6465 | 0.500 |
Why?
|
| Gallbladder | 1 | 2017 | 305 | 0.500 |
Why?
|
| Camptothecin | 5 | 2017 | 590 | 0.500 |
Why?
|
| Gastrointestinal Diseases | 3 | 2019 | 1190 | 0.500 |
Why?
|
| Protons | 6 | 2023 | 1114 | 0.490 |
Why?
|
| Lymphatic Metastasis | 13 | 2018 | 2943 | 0.490 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 10 | 2019 | 1728 | 0.470 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2005 | 136 | 0.460 |
Why?
|
| Respiration | 4 | 2013 | 1654 | 0.440 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2016 | 294 | 0.430 |
Why?
|
| Portal Vein | 2 | 2023 | 429 | 0.430 |
Why?
|
| Follow-Up Studies | 22 | 2024 | 39261 | 0.430 |
Why?
|
| Neoplasm, Residual | 5 | 2021 | 1007 | 0.420 |
Why?
|
| Brachytherapy | 3 | 2019 | 1238 | 0.420 |
Why?
|
| Blood Vessels | 1 | 2018 | 1112 | 0.410 |
Why?
|
| Ketamine | 1 | 2018 | 516 | 0.410 |
Why?
|
| Mitomycin | 5 | 2019 | 262 | 0.400 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2016 | 1131 | 0.400 |
Why?
|
| Receptor, erbB-2 | 2 | 2022 | 2554 | 0.400 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2019 | 2053 | 0.390 |
Why?
|
| Dose-Response Relationship, Radiation | 6 | 2018 | 881 | 0.390 |
Why?
|
| Adult | 70 | 2024 | 219994 | 0.380 |
Why?
|
| Molecular Targeted Therapy | 7 | 2021 | 2803 | 0.380 |
Why?
|
| Autophagy | 2 | 2018 | 1337 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 6544 | 0.370 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2015 | 296 | 0.360 |
Why?
|
| Papillomaviridae | 1 | 2016 | 1117 | 0.360 |
Why?
|
| Antineoplastic Agents | 19 | 2020 | 13630 | 0.360 |
Why?
|
| Surgical Mesh | 1 | 2013 | 311 | 0.360 |
Why?
|
| Astrocytes | 1 | 2018 | 1338 | 0.360 |
Why?
|
| Hypoglycemic Agents | 3 | 2014 | 3150 | 0.360 |
Why?
|
| Prospective Studies | 24 | 2024 | 54303 | 0.350 |
Why?
|
| Aluminum Oxide | 1 | 2009 | 41 | 0.350 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 517 | 0.340 |
Why?
|
| Electrochemistry | 1 | 2009 | 143 | 0.340 |
Why?
|
| Radiation Protection | 1 | 2013 | 425 | 0.340 |
Why?
|
| Spine | 1 | 2016 | 1111 | 0.340 |
Why?
|
| Relative Biological Effectiveness | 3 | 2018 | 312 | 0.340 |
Why?
|
| Thrombosis | 2 | 2023 | 3052 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2020 | 567 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 7 | 2023 | 3618 | 0.330 |
Why?
|
| Silicon | 1 | 2009 | 142 | 0.330 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 11345 | 0.320 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1056 | 0.320 |
Why?
|
| Microelectrodes | 1 | 2009 | 304 | 0.310 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2019 | 508 | 0.310 |
Why?
|
| Consensus | 5 | 2020 | 3113 | 0.310 |
Why?
|
| Models, Statistical | 3 | 2020 | 5075 | 0.310 |
Why?
|
| Lighting | 1 | 2009 | 211 | 0.290 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2007 | 90 | 0.290 |
Why?
|
| Radiometry | 3 | 2020 | 813 | 0.290 |
Why?
|
| Mutation | 16 | 2020 | 29932 | 0.280 |
Why?
|
| Rectum | 6 | 2023 | 895 | 0.280 |
Why?
|
| Colon | 2 | 2020 | 1788 | 0.280 |
Why?
|
| ras Proteins | 5 | 2014 | 1052 | 0.280 |
Why?
|
| Supratentorial Neoplasms | 2 | 2005 | 159 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2024 | 36290 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2024 | 5253 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 6 | 2021 | 9185 | 0.270 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 273 | 0.260 |
Why?
|
| Hepatectomy | 2 | 2020 | 559 | 0.260 |
Why?
|
| Neuroendocrine Tumors | 1 | 2012 | 650 | 0.250 |
Why?
|
| Biological Products | 2 | 2019 | 916 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2448 | 0.250 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 4107 | 0.250 |
Why?
|
| Palliative Care | 2 | 2020 | 3607 | 0.250 |
Why?
|
| Lung Neoplasms | 7 | 2019 | 13262 | 0.250 |
Why?
|
| Anal Canal | 4 | 2021 | 372 | 0.240 |
Why?
|
| Esophagectomy | 4 | 2017 | 466 | 0.240 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 3844 | 0.240 |
Why?
|
| Cisplatin | 5 | 2023 | 1644 | 0.240 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 1299 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2021 | 20509 | 0.240 |
Why?
|
| Nanostructures | 1 | 2009 | 547 | 0.240 |
Why?
|
| Survival Analysis | 9 | 2019 | 10182 | 0.240 |
Why?
|
| Carcinoma | 1 | 2016 | 2331 | 0.240 |
Why?
|
| Parotid Gland | 1 | 2005 | 175 | 0.240 |
Why?
|
| Nanotechnology | 1 | 2009 | 709 | 0.230 |
Why?
|
| Immunotherapy | 7 | 2023 | 4642 | 0.230 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 716 | 0.220 |
Why?
|
| Brain Neoplasms | 3 | 2018 | 8986 | 0.220 |
Why?
|
| Pelvis | 5 | 2020 | 743 | 0.220 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2014 | 180 | 0.220 |
Why?
|
| Gallbladder Neoplasms | 2 | 2018 | 190 | 0.220 |
Why?
|
| Treatment Failure | 5 | 2019 | 2648 | 0.210 |
Why?
|
| Esthetics, Dental | 2 | 2022 | 268 | 0.210 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 12531 | 0.210 |
Why?
|
| Carboplatin | 3 | 2022 | 788 | 0.210 |
Why?
|
| Patient Selection | 6 | 2023 | 4283 | 0.200 |
Why?
|
| Neoplasms | 9 | 2023 | 22072 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2016 | 2864 | 0.200 |
Why?
|
| GTP Phosphohydrolases | 3 | 2014 | 518 | 0.200 |
Why?
|
| Contrast Media | 1 | 2015 | 5305 | 0.200 |
Why?
|
| Salvage Therapy | 3 | 2020 | 1268 | 0.200 |
Why?
|
| CA-19-9 Antigen | 3 | 2022 | 106 | 0.200 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 5761 | 0.200 |
Why?
|
| Maxilla | 2 | 2022 | 491 | 0.200 |
Why?
|
| Lymphatic Irradiation | 3 | 2010 | 115 | 0.200 |
Why?
|
| Pilot Projects | 3 | 2021 | 8555 | 0.200 |
Why?
|
| Radiography | 6 | 2013 | 6965 | 0.200 |
Why?
|
| Quality of Life | 9 | 2024 | 13308 | 0.200 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 224 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 2 | 2022 | 707 | 0.190 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2014 | 336 | 0.190 |
Why?
|
| Diarrhea | 3 | 2015 | 1319 | 0.190 |
Why?
|
| Disease Progression | 9 | 2022 | 13502 | 0.190 |
Why?
|
| Medical Illustration | 2 | 2015 | 135 | 0.190 |
Why?
|
| Standard of Care | 3 | 2022 | 552 | 0.190 |
Why?
|
| Microsatellite Instability | 2 | 2016 | 715 | 0.190 |
Why?
|
| Collagen Type I | 1 | 2024 | 616 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2014 | 4490 | 0.180 |
Why?
|
| Cell Line, Tumor | 13 | 2024 | 16939 | 0.180 |
Why?
|
| Nerve Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
| Patient Participation | 1 | 2010 | 1439 | 0.180 |
Why?
|
| Duodenum | 1 | 2023 | 486 | 0.180 |
Why?
|
| Rotavirus | 1 | 2001 | 110 | 0.180 |
Why?
|
| Metformin | 1 | 2008 | 912 | 0.180 |
Why?
|
| Dinoprostone | 1 | 2023 | 598 | 0.170 |
Why?
|
| Massachusetts | 4 | 2020 | 8803 | 0.170 |
Why?
|
| HMGA2 Protein | 1 | 2020 | 102 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 2919 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 4899 | 0.170 |
Why?
|
| Microsatellite Repeats | 1 | 2021 | 786 | 0.160 |
Why?
|
| Radiation Dosage | 3 | 2017 | 1958 | 0.160 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2000 | 354 | 0.160 |
Why?
|
| Colostomy | 1 | 2019 | 105 | 0.160 |
Why?
|
| Mice, Nude | 4 | 2024 | 3607 | 0.160 |
Why?
|
| Preoperative Period | 2 | 2022 | 555 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2015 | 929 | 0.150 |
Why?
|
| Liver | 5 | 2022 | 7509 | 0.150 |
Why?
|
| Bilirubin | 1 | 2020 | 438 | 0.150 |
Why?
|
| Movement | 3 | 2011 | 1474 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 117 | 0.150 |
Why?
|
| Capsid Proteins | 1 | 2001 | 467 | 0.150 |
Why?
|
| Paclitaxel | 3 | 2022 | 1736 | 0.150 |
Why?
|
| Stomach | 3 | 2013 | 694 | 0.150 |
Why?
|
| Hydrogels | 1 | 2023 | 723 | 0.150 |
Why?
|
| Hepadnaviridae | 1 | 2017 | 1 | 0.150 |
Why?
|
| Sheep | 1 | 2000 | 1441 | 0.150 |
Why?
|
| I-kappa B Proteins | 1 | 2018 | 212 | 0.150 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 9411 | 0.150 |
Why?
|
| Models, Biological | 4 | 2018 | 9467 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 12293 | 0.150 |
Why?
|
| Disulfiram | 1 | 2017 | 63 | 0.140 |
Why?
|
| Antigens, Viral | 1 | 2001 | 980 | 0.140 |
Why?
|
| Colonoscopy | 2 | 2016 | 1387 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2024 | 8515 | 0.140 |
Why?
|
| Neurosciences | 1 | 2022 | 353 | 0.140 |
Why?
|
| Preoperative Care | 4 | 2015 | 2256 | 0.140 |
Why?
|
| Conus Snail | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pelvic Bones | 2 | 2017 | 270 | 0.140 |
Why?
|
| Algorithms | 6 | 2015 | 13981 | 0.140 |
Why?
|
| Serum Albumin | 1 | 2020 | 674 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2017 | 141 | 0.140 |
Why?
|
| Cauda Equina | 1 | 2016 | 45 | 0.140 |
Why?
|
| Angiotensins | 1 | 2017 | 143 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2506 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2017 | 221 | 0.140 |
Why?
|
| DNA, Neoplasm | 2 | 2019 | 1745 | 0.140 |
Why?
|
| Epirubicin | 1 | 2016 | 83 | 0.140 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2018 | 550 | 0.140 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 717 | 0.140 |
Why?
|
| Pulmonary Valve | 1 | 2000 | 414 | 0.130 |
Why?
|
| Fiducial Markers | 2 | 2015 | 132 | 0.130 |
Why?
|
| Peritoneum | 1 | 2017 | 224 | 0.130 |
Why?
|
| Radiopharmaceuticals | 5 | 2024 | 2634 | 0.130 |
Why?
|
| Software | 2 | 2017 | 4419 | 0.130 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2018 | 167 | 0.130 |
Why?
|
| Genetic Heterogeneity | 2 | 2019 | 724 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 5 | 2022 | 7475 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2017 | 5251 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2016 | 895 | 0.130 |
Why?
|
| Recombinases | 1 | 2016 | 66 | 0.130 |
Why?
|
| Hospitals, General | 1 | 2020 | 795 | 0.130 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 2001 | 0.130 |
Why?
|
| Cholelithiasis | 1 | 2017 | 408 | 0.130 |
Why?
|
| Karyopherins | 1 | 2015 | 130 | 0.120 |
Why?
|
| Bone Marrow Diseases | 1 | 2017 | 232 | 0.120 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2019 | 607 | 0.120 |
Why?
|
| Osteopontin | 1 | 2017 | 302 | 0.120 |
Why?
|
| Animals | 22 | 2024 | 167963 | 0.120 |
Why?
|
| Dura Mater | 1 | 2016 | 290 | 0.120 |
Why?
|
| Neutropenia | 2 | 2017 | 884 | 0.120 |
Why?
|
| Apoptosis | 4 | 2018 | 9501 | 0.120 |
Why?
|
| Informed Consent | 1 | 2021 | 1005 | 0.120 |
Why?
|
| Neural Tube Defects | 1 | 2016 | 254 | 0.120 |
Why?
|
| Cecal Neoplasms | 1 | 2014 | 26 | 0.120 |
Why?
|
| Lymph Node Excision | 5 | 2016 | 1303 | 0.120 |
Why?
|
| Receptors, CXCR | 1 | 2014 | 52 | 0.120 |
Why?
|
| Chromones | 1 | 2014 | 149 | 0.120 |
Why?
|
| Community Health Centers | 1 | 2017 | 453 | 0.110 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 331 | 0.110 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2015 | 125 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2020 | 10344 | 0.110 |
Why?
|
| Urogenital System | 2 | 2010 | 88 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 730 | 0.110 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2011 | 144 | 0.110 |
Why?
|
| Dental Implants | 1 | 2022 | 791 | 0.110 |
Why?
|
| Postoperative Period | 2 | 2016 | 1818 | 0.110 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 286 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2024 | 23376 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Ankle | 1 | 2013 | 25 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 938 | 0.110 |
Why?
|
| Receptors, Glucagon | 1 | 2013 | 90 | 0.110 |
Why?
|
| Arteriovenous Fistula | 1 | 2016 | 314 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 5889 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2020 | 2209 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 734 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 3726 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1385 | 0.110 |
Why?
|
| Endonucleases | 1 | 2016 | 370 | 0.110 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 243 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2024 | 3215 | 0.110 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2013 | 131 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2019 | 1355 | 0.110 |
Why?
|
| Time Factors | 11 | 2021 | 40165 | 0.110 |
Why?
|
| Risk Factors | 10 | 2022 | 74359 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 267 | 0.100 |
Why?
|
| Back Pain | 1 | 2016 | 543 | 0.100 |
Why?
|
| Genotype | 3 | 2017 | 12960 | 0.100 |
Why?
|
| Digestive System | 1 | 2013 | 244 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 2 | 2017 | 1347 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3584 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3085 | 0.100 |
Why?
|
| Arthritis | 1 | 2018 | 666 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2017 | 372 | 0.100 |
Why?
|
| Deglutition Disorders | 2 | 2016 | 626 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1588 | 0.100 |
Why?
|
| Intestine, Large | 1 | 2012 | 68 | 0.100 |
Why?
|
| Androstadienes | 1 | 2014 | 348 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3205 | 0.100 |
Why?
|
| Glutarates | 1 | 2014 | 244 | 0.100 |
Why?
|
| Affect | 1 | 2020 | 1480 | 0.100 |
Why?
|
| Cyclin D1 | 1 | 2013 | 451 | 0.100 |
Why?
|
| Young Adult | 12 | 2022 | 58741 | 0.100 |
Why?
|
| Genes, ras | 1 | 2014 | 655 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 1796 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 1894 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2015 | 854 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 1098 | 0.090 |
Why?
|
| Europe | 2 | 2015 | 3441 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 2276 | 0.090 |
Why?
|
| Morpholines | 1 | 2014 | 583 | 0.090 |
Why?
|
| United States | 14 | 2023 | 72461 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1484 | 0.090 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2014 | 380 | 0.090 |
Why?
|
| Actuarial Analysis | 1 | 2010 | 374 | 0.090 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2014 | 329 | 0.090 |
Why?
|
| Defecation | 1 | 2012 | 190 | 0.090 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 4902 | 0.090 |
Why?
|
| Age Factors | 5 | 2023 | 18416 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2017 | 1535 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 594 | 0.090 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 509 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 20080 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2086 | 0.090 |
Why?
|
| Biopsy | 3 | 2019 | 6771 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 11071 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8624 | 0.090 |
Why?
|
| Incidence | 6 | 2021 | 21392 | 0.090 |
Why?
|
| Perioperative Care | 2 | 2018 | 1037 | 0.090 |
Why?
|
| Duodenal Neoplasms | 1 | 2010 | 115 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2000 | 1582 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2018 | 2488 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2019 | 1413 | 0.080 |
Why?
|
| Gingiva | 2 | 2022 | 406 | 0.080 |
Why?
|
| Uncertainty | 1 | 2014 | 754 | 0.080 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 708 | 0.080 |
Why?
|
| Vagina | 1 | 2014 | 837 | 0.080 |
Why?
|
| Semiconductors | 1 | 2009 | 99 | 0.080 |
Why?
|
| Bone Marrow | 2 | 2017 | 2912 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2020 | 2511 | 0.080 |
Why?
|
| Failure to Thrive | 1 | 2009 | 140 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 675 | 0.080 |
Why?
|
| Crystallization | 1 | 2009 | 533 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 785 | 0.080 |
Why?
|
| Membrane Proteins | 3 | 2014 | 7850 | 0.080 |
Why?
|
| SEER Program | 4 | 2018 | 1530 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2009 | 548 | 0.080 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 780 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2020 | 296 | 0.080 |
Why?
|
| Rats | 5 | 2018 | 23711 | 0.080 |
Why?
|
| Observer Variation | 1 | 2014 | 2601 | 0.080 |
Why?
|
| Cause of Death | 1 | 2019 | 3725 | 0.080 |
Why?
|
| Simplexvirus | 2 | 1982 | 803 | 0.080 |
Why?
|
| Cytarabine | 1 | 2010 | 696 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 4357 | 0.080 |
Why?
|
| Drug Substitution | 1 | 2010 | 296 | 0.070 |
Why?
|
| Gastrointestinal Tract | 2 | 2010 | 830 | 0.070 |
Why?
|
| Pain | 3 | 2013 | 5066 | 0.070 |
Why?
|
| Adolescent | 7 | 2023 | 87810 | 0.070 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2008 | 211 | 0.070 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2022 | 471 | 0.070 |
Why?
|
| Prescriptions | 1 | 2010 | 388 | 0.070 |
Why?
|
| Medical Oncology | 3 | 2016 | 2313 | 0.070 |
Why?
|
| Motion | 2 | 2011 | 779 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3616 | 0.070 |
Why?
|
| Electrodes | 1 | 2009 | 614 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 3388 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 8158 | 0.070 |
Why?
|
| Chordoma | 1 | 2010 | 346 | 0.070 |
Why?
|
| Quinazolines | 1 | 2014 | 1363 | 0.070 |
Why?
|
| Equipment Failure Analysis | 1 | 2009 | 848 | 0.070 |
Why?
|
| Skull Base Neoplasms | 1 | 2010 | 269 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 1008 | 0.070 |
Why?
|
| Particle Accelerators | 2 | 2021 | 174 | 0.070 |
Why?
|
| Forecasting | 1 | 2016 | 2932 | 0.070 |
Why?
|
| Surface Properties | 1 | 2009 | 1161 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 496 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 1186 | 0.070 |
Why?
|
| Cell Movement | 2 | 2020 | 5206 | 0.070 |
Why?
|
| DNA Repair | 1 | 2016 | 2039 | 0.070 |
Why?
|
| Nausea | 1 | 2009 | 678 | 0.070 |
Why?
|
| Thoracic Neoplasms | 1 | 2008 | 266 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 12965 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2020 | 3790 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 1096 | 0.070 |
Why?
|
| Automation | 1 | 2008 | 580 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2001 | 6551 | 0.070 |
Why?
|
| Vomiting | 1 | 2009 | 650 | 0.070 |
Why?
|
| Materials Testing | 1 | 2009 | 862 | 0.070 |
Why?
|
| Recurrence | 2 | 2011 | 8482 | 0.070 |
Why?
|
| Mice | 10 | 2024 | 81208 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2015 | 3696 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 5799 | 0.070 |
Why?
|
| Proteolipids | 1 | 2005 | 113 | 0.060 |
Why?
|
| Abdomen | 1 | 2011 | 1130 | 0.060 |
Why?
|
| Intraoperative Period | 2 | 2019 | 516 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2020 | 15697 | 0.060 |
Why?
|
| Thymus Neoplasms | 1 | 2008 | 274 | 0.060 |
Why?
|
| Particle Size | 1 | 2009 | 1644 | 0.060 |
Why?
|
| Disease Management | 1 | 2016 | 2514 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2005 | 150 | 0.060 |
Why?
|
| Colectomy | 1 | 2010 | 692 | 0.060 |
Why?
|
| Pulmonary Surfactants | 1 | 2005 | 161 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2017 | 2147 | 0.060 |
Why?
|
| Protein Structure, Secondary | 2 | 2005 | 1229 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2006 | 298 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 1405 | 0.060 |
Why?
|
| Infratentorial Neoplasms | 1 | 2005 | 98 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6238 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15289 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 961 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 5643 | 0.060 |
Why?
|
| Immobilization | 1 | 2005 | 230 | 0.060 |
Why?
|
| Propensity Score | 2 | 2023 | 1928 | 0.060 |
Why?
|
| Peptide Fragments | 3 | 2008 | 5125 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2852 | 0.060 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2023 | 2611 | 0.060 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 106 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 2895 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2873 | 0.050 |
Why?
|
| Adenoma | 1 | 2014 | 2148 | 0.050 |
Why?
|
| Mesenteric Veins | 1 | 2023 | 85 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2014 | 3112 | 0.050 |
Why?
|
| Comorbidity | 3 | 2018 | 10551 | 0.050 |
Why?
|
| Troponin T | 1 | 2008 | 774 | 0.050 |
Why?
|
| Cohort Studies | 7 | 2020 | 41335 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4878 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2014 | 8313 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2014 | 4563 | 0.050 |
Why?
|
| RNA Viruses | 1 | 1983 | 110 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10446 | 0.050 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2001 | 354 | 0.050 |
Why?
|
| Quality Control | 1 | 2005 | 828 | 0.050 |
Why?
|
| Tooth Crown | 1 | 2022 | 61 | 0.050 |
Why?
|
| Lung Injury | 1 | 2007 | 424 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 1345 | 0.050 |
Why?
|
| Equipment Design | 1 | 2009 | 3520 | 0.050 |
Why?
|
| Life Cycle Stages | 1 | 2022 | 160 | 0.050 |
Why?
|
| Protein Precursors | 1 | 2005 | 1134 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 861 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 9585 | 0.050 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2022 | 114 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2015 | 24123 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 3765 | 0.050 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 1392 | 0.050 |
Why?
|
| Incisor | 1 | 2022 | 174 | 0.050 |
Why?
|
| Fractals | 1 | 2021 | 128 | 0.050 |
Why?
|
| Sequence Analysis | 1 | 2001 | 240 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2001 | 218 | 0.050 |
Why?
|
| Lamivudine | 1 | 2022 | 363 | 0.050 |
Why?
|
| Rotavirus Infections | 1 | 2001 | 85 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 12159 | 0.040 |
Why?
|
| Alveolar Process | 1 | 2022 | 294 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 10181 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 240 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2002 | 549 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2010 | 5961 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2021 | 238 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2022 | 673 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2002 | 391 | 0.040 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2019 | 7 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 14660 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 1717 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 5791 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 656 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2007 | 2512 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2016 | 42063 | 0.040 |
Why?
|
| Models, Theoretical | 2 | 2021 | 3562 | 0.040 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2018 | 45 | 0.040 |
Why?
|
| Therapeutic Uses | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cystectomy | 1 | 2023 | 697 | 0.040 |
Why?
|
| Interferons | 1 | 2022 | 705 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 13451 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
| Cell Survival | 2 | 2019 | 5797 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2001 | 412 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2020 | 203 | 0.040 |
Why?
|
| Sex Factors | 1 | 2012 | 10547 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2019 | 191 | 0.040 |
Why?
|
| Depression | 1 | 2017 | 8044 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 152 | 0.040 |
Why?
|
| Aspirin | 1 | 1990 | 3364 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2005 | 17624 | 0.040 |
Why?
|
| Body Weight | 1 | 2008 | 4611 | 0.040 |
Why?
|
| Fibrosis | 1 | 2024 | 2042 | 0.040 |
Why?
|
| Cell Communication | 1 | 2024 | 1653 | 0.040 |
Why?
|
| Barium | 1 | 2016 | 62 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2018 | 310 | 0.040 |
Why?
|
| Lipids | 1 | 2008 | 3336 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 305 | 0.030 |
Why?
|
| Pancreas | 1 | 2023 | 1677 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1981 | 1516 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 357 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 5508 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2008 | 2003 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 2016 | 38 | 0.030 |
Why?
|
| Cobalt Radioisotopes | 1 | 2016 | 75 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2019 | 423 | 0.030 |
Why?
|
| Length of Stay | 1 | 2010 | 6479 | 0.030 |
Why?
|
| Organoids | 1 | 2022 | 729 | 0.030 |
Why?
|
| Radiation | 1 | 2015 | 48 | 0.030 |
Why?
|
| Peptides | 2 | 2005 | 4354 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2019 | 370 | 0.030 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1997 | 151 | 0.030 |
Why?
|
| Kidney | 2 | 2011 | 7064 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3610 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1837 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1612 | 0.030 |
Why?
|
| Autopsy | 1 | 2019 | 1007 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2011 | 3484 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2014 | 1479 | 0.030 |
Why?
|
| Linear Models | 2 | 2016 | 5877 | 0.030 |
Why?
|
| Child | 3 | 2016 | 79806 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 15840 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 529 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 783 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 188 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2017 | 232 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 646 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 2627 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 197 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 10827 | 0.030 |
Why?
|
| Copper | 1 | 2017 | 368 | 0.030 |
Why?
|
| Japan | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Endodeoxyribonucleases | 1 | 2016 | 164 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 998 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18137 | 0.030 |
Why?
|
| Colon, Ascending | 1 | 2014 | 14 | 0.030 |
Why?
|
| Spiral Cone-Beam Computed Tomography | 1 | 2015 | 34 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1440 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2019 | 1199 | 0.030 |
Why?
|
| Stomach Diseases | 1 | 2015 | 133 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2002 | 916 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 1189 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 1246 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3959 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 1004 | 0.030 |
Why?
|
| Hydrazines | 1 | 2015 | 224 | 0.030 |
Why?
|
| Polyps | 1 | 2015 | 197 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 8056 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2014 | 195 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2017 | 967 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2008 | 6381 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2017 | 442 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2019 | 8035 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2019 | 753 | 0.030 |
Why?
|
| Edema | 1 | 1997 | 769 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 788 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 1289 | 0.030 |
Why?
|
| Fanconi Anemia | 1 | 2016 | 324 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 2380 | 0.030 |
Why?
|
| Phthalazines | 1 | 2016 | 383 | 0.030 |
Why?
|
| Triage | 1 | 2020 | 987 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2018 | 4550 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 1257 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3568 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1091 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 2394 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2001 | 7408 | 0.030 |
Why?
|
| Pyrazines | 1 | 2019 | 1199 | 0.030 |
Why?
|
| Infant | 2 | 2005 | 36060 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 1724 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 345 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2722 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 1900 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 551 | 0.020 |
Why?
|
| Endosonography | 1 | 2015 | 607 | 0.020 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2011 | 95 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2018 | 787 | 0.020 |
Why?
|
| Cadherins | 1 | 2016 | 898 | 0.020 |
Why?
|
| Body Burden | 1 | 2011 | 158 | 0.020 |
Why?
|
| Circular Dichroism | 2 | 2001 | 348 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 1998 | 0.020 |
Why?
|
| Hospitalization | 1 | 2011 | 10790 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 429 | 0.020 |
Why?
|
| Ions | 1 | 2011 | 261 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8950 | 0.020 |
Why?
|
| Esophagus | 1 | 2016 | 1023 | 0.020 |
Why?
|
| Analgesics | 1 | 1997 | 1065 | 0.020 |
Why?
|
| Guaiacol | 1 | 1990 | 5 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 1693 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 1075 | 0.020 |
Why?
|
| Triazoles | 1 | 2015 | 904 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 832 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2022 | 3061 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1983 | 2558 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 1088 | 0.020 |
Why?
|
| Salicylates | 1 | 1990 | 127 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2013 | 435 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2014 | 551 | 0.020 |
Why?
|
| China | 1 | 2015 | 2339 | 0.020 |
Why?
|
| Inguinal Canal | 1 | 2008 | 71 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2203 | 0.020 |
Why?
|
| Computational Biology | 1 | 2021 | 3505 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2018 | 2566 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 532 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1999 | 4000 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7233 | 0.020 |
Why?
|
| Ilium | 1 | 2008 | 154 | 0.020 |
Why?
|
| Neutrophils | 1 | 2021 | 3767 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 1206 | 0.020 |
Why?
|
| Lung | 1 | 2007 | 9994 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 3707 | 0.020 |
Why?
|
| Morphogenesis | 2 | 1982 | 740 | 0.020 |
Why?
|
| Carbon | 1 | 2011 | 669 | 0.020 |
Why?
|
| Genomics | 1 | 2023 | 5794 | 0.020 |
Why?
|
| Glioma | 1 | 2002 | 3420 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 15757 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 2753 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2009 | 351 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 2254 | 0.020 |
Why?
|
| Proteins | 1 | 2001 | 6029 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1931 | 0.020 |
Why?
|
| Acute Disease | 1 | 2017 | 7269 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 21025 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5039 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7806 | 0.020 |
Why?
|
| Xerostomia | 1 | 2006 | 94 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2005 | 160 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1990 | 2262 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 2013 | 1055 | 0.020 |
Why?
|
| Transfection | 1 | 2013 | 5781 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2008 | 987 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4353 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 5870 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2525 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3775 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2001 | 1949 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14372 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 2907 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 1153 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2016 | 3905 | 0.010 |
Why?
|
| Gastrostomy | 1 | 2006 | 321 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 14495 | 0.010 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2008 | 421 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2013 | 3528 | 0.010 |
Why?
|
| Reoperation | 1 | 2013 | 4291 | 0.010 |
Why?
|
| Macrophages | 1 | 2018 | 5745 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2017 | 3323 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 5785 | 0.010 |
Why?
|
| Intestines | 1 | 2011 | 1907 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 18957 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4775 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2001 | 82 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2009 | 816 | 0.010 |
Why?
|
| Reference Values | 1 | 2009 | 4925 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2010 | 1442 | 0.010 |
Why?
|
| Cathelicidins | 1 | 2001 | 81 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3465 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 4048 | 0.010 |
Why?
|
| Staphylococcus epidermidis | 1 | 2001 | 122 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3202 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16546 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2010 | 6360 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6786 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1983 | 1705 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11481 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 4373 | 0.010 |
Why?
|
| Logistic Models | 1 | 2014 | 13314 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 2001 | 248 | 0.010 |
Why?
|
| Ferritins | 1 | 1982 | 597 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2017 | 12914 | 0.010 |
Why?
|
| Kangai-1 Protein | 1 | 1999 | 22 | 0.010 |
Why?
|
| Virion | 1 | 1981 | 421 | 0.010 |
Why?
|
| Escherichia coli | 2 | 2001 | 4219 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22023 | 0.010 |
Why?
|
| Hearing Loss | 1 | 2006 | 780 | 0.010 |
Why?
|
| Decision Making | 1 | 2012 | 3925 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 1991 | 0.010 |
Why?
|
| Otitis | 1 | 1997 | 21 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1978 | 94 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 777 | 0.010 |
Why?
|
| Tablets | 1 | 1997 | 149 | 0.010 |
Why?
|
| Zinc | 1 | 2001 | 689 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1978 | 238 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 2502 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2011 | 4360 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 1927 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2001 | 2316 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1981 | 3105 | 0.010 |
Why?
|
| Weight Loss | 1 | 2006 | 2686 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 3800 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1997 | 768 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1997 | 1850 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 2209 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17790 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2001 | 3969 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2002 | 2145 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1997 | 2025 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12446 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 8010 | 0.000 |
Why?
|
| Cell Line | 1 | 1981 | 15620 | 0.000 |
Why?
|
| Methods | 1 | 1978 | 1074 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1978 | 1628 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1978 | 26181 | 0.000 |
Why?
|